TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. TransCode Therapeutics Stock Performance Shares of RNAZ traded down $0.01 during trading hours on Wednesday, reaching $0.67. 138,372 shares of the company traded hands, compared to its […]
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) TransCode Therapeutics, Inc. RNAZ, the RNA oncology company committed to more effectively treating cancer using RNA…
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders Equity Requirement and Continued Listing on The Nasdaq Stock Market tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.